The Medical Letter on Drugs and Therapeutics
Subcutaneous Immune Globulin (SCIG)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Some patients with primary immune deficiency are injected with intravenous immune globulin (IVIG) every 3-4 weeks.1 Now a subcutaneous immune globulin (SCIG) has also been approved in the US for this indication (Vivaglobin – CSL Behring). SCIG has been used in Europe for about 10 years.

PHARMACOKINETICS — To achieve the same AUC (area under the plasma concentration-time curve) as IVIG, the cumulative dose of SCIG, which is given more frequently, must be 1.37 times the IV dose. At that dose, SCIG produces serum concentrations of IgG that are lower at peak but higher at trough than IVIG.

CLINICAL STUDIES — Two clinical studies of Vivaglobin use in primary immune deficiency have been published. One was a 6-month open-label study in 60 adults and children from Europe and Brazil with primary immune deficiency, and the other was a 12-month study in 65 adults ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Subcutaneous Immune Globulin (SCIG)
Article code: 1258b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian